Premium
S4‐02–03: TDZDS: Can we target tau, beta‐amyloid and neurodegeneration simultaneously?
Author(s) -
Martinez Ana
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.481
Subject(s) - neurodegeneration , gsk 3 , neuroprotection , excitotoxicity , neurofibrillary tangle , medicine , genetically modified mouse , neuroscience , amyloid beta , pharmacology , transgene , alzheimer's disease , disease , kinase , pathology , biology , senile plaques , glutamate receptor , receptor , biochemistry , gene
and neuronal death. In animal models, growth factors prevent neuronal death and restore synaptic function. In ongoing programs, we are testing the therapeutic potential of growth factors to influence neurodegeneration in AD. Methods: To test the therapeutic potential of growth factors in animal models and human clinical trials, a delivery method is required that achieves adequate concentrations of growth factors over sustained time periods, while limiting distribution of growth factors to regions of degenerating neurons to avoid adverse effects. Results: We will discuss recent advances in clinical trials of Nerve Growth Factor gene delivery in AD and Brain Derived Neurotrophic Factor gene delivery in animal models of AD. Conclusions: Overall, these studies support the concept that growth factors reduce the consequences of toxic and traumatic insults to neurons, including those arising from A-beta related mechanisms.